Bill & Melinda Gates Foundation Trust
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people - especially those with the fewest resources - have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.
-
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
-
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
-
Moderna (MRNA) Partners with IAVI to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
-
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
-
Moderna (MRNA) Provides Update on Clinical Programs at 3rd Annual Vaccines Day
-
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
-
Moderna (MRNA) Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
-
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
-
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
-
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
-
Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
-
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
-
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
-
Moderna (MRNA) announces interim Phase 1 data from RSV vaccine candidate and new 7-month interim Phase 2 data from its CMV vaccine candidate
-
Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development
-
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
-
Moderna (MRNA) Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
-
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
-
Moderna (MRNA) CEO Issues Letter to Shareholders
-
Flagship Pioneering Strengthens Leadership with Appointment of Christine Heenan as Senior Partner and Chief Communications Officer
-
U.S. sets global benchmark for COVID-19 vaccine price at around the cost of a flu shot
-
Exclusive: Vaccine alliance finds manufacturing capacity for 4 billion doses of coronavirus vaccines
-
Moderna (MRNA) Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day
-
Moderna (MRNA) Provides Update on Business Operations Related to COVID-19
-
Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development
-
Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities
-
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
-
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
